Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Consensus Price Target of $10.00 According to Brokerages

Shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Get Free Report) have been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.00.

Several equities research analysts have recently issued reports on ATHE shares. Lake Street Capital assumed coverage on shares of Alterity Therapeutics in a research report on Tuesday, September 15th. They issued a “buy” rating and a $10.00 price objective for the company. UBS Group set a $12.00 target price on shares of Alterity Therapeutics in a report on Tuesday, August 11th. Weiss Ratings cut shares of Alterity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. Finally, Craig Hallum set a $2.00 price target on Alterity Therapeutics in a report on Tuesday, August 11th.

Get Our Latest Stock Analysis on Alterity Therapeutics

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. Greenleaf Trust boosted its stake in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Free Report) by 93.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 62,000 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Greenleaf Trust owned about 0.70% of Alterity Therapeutics worth $333,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Price Performance

ATHE stock opened at $1.52 on Thursday. Alterity Therapeutics has a 52 week low of $1.52 and a 52 week high of $5.89. The company’s 50-day moving average price is $2.78 and its 200 day moving average price is $3.88.

Alterity Therapeutics (NASDAQ:ATHE – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.28) EPS for the quarter. The company had revenue of $0.31 million for the quarter. On average, research analysts expect that Alterity Therapeutics will post -0.12 earnings per share for the current fiscal year.

About Alterity Therapeutics

(Get Free Report)

Alterity Therapeutics is an Australian clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on conditions associated with abnormal protein accumulation and disrupted iron balance in the brain, including multiple system atrophy (MSA) and Parkinson’s disease. The company’s lead candidate, ATH434, is an investigational small-molecule therapy being studied for MSA. Alterity is evaluating the treatment in clinical trials; it is not an approved medicine.

See Also

Analyst Recommendations for Alterity Therapeutics (NASDAQ:ATHE)

Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.